InvestorsHub Logo
Followers 1
Posts 1178
Boards Moderated 0
Alias Born 02/01/2013

Re: None

Friday, 01/04/2019 3:20:59 PM

Friday, January 04, 2019 3:20:59 PM

Post# of 108192
Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies for the Treatment of Cancer

“We believe targeting neoantigens could be the most effective approach for harnessing a person’s immune system to fight cancer,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “This partnership, which combines Adaptive’s pioneering platform for identifying T-cell receptors with Genentech’s cancer immunology expertise, has the potential to change the way cancer is treated and bring us one step closer to truly personalized healthcare.”

https://www.businesswire.com/news/home/20190104005112/en/Adaptive-Biotechnologies-Enter-Worldwide-Collaboration-License-Agreement
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News